Mobia Medical (NASDAQ:MOBI) Director Casey Tansey Acquires 17,166 Shares of Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 17,166 shares of Mobia Medical stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average price of $11.85 per share, with a total value of $203,417.10. Following the acquisition, the director directly owned 301,891 shares of the company’s stock, valued at $3,577,408.35. The trade was a 6.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mobia Medical Trading Down 0.2%

Mobia Medical stock opened at $11.74 on Tuesday. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. Mobia Medical, Inc. has a 1-year low of $10.19 and a 1-year high of $15.29. The company has a fifty day simple moving average of $12.42. The company has a market capitalization of $390.84 million and a P/E ratio of -0.61.

Mobia Medical (NASDAQ:MOBI) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The business’s quarterly revenue was up 102.4% compared to the same quarter last year. On average, equities research analysts forecast that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on MOBI shares. Bank of America initiated coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price target on the stock. Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Weiss Ratings initiated coverage on shares of Mobia Medical in a research note on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Wolfe Research initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set an “outperform” rating on the stock. Finally, Zacks Research raised shares of Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.